PetDx: Funding, Investors & Team (Sep 2026)
PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.
PetDx has raised $62.0M across 1 funding round on record, the most recent a Series B of $62.0M announced in Dec 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
PetDx Company Profile and Key Stats
Latest funding round on record: Dec 2021.
PetDx Funding Rounds
PetDx Founders and Leadership Team
Contact details for the PetDx team: 1 of 1 has an email address on file.
Start 14-day free trial →PetDx Funding Compared to Other Biotechnology Startups
PetDx's latest round of $62.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like PetDx in Biotechnology and La Jolla
Companies Similar to PetDx
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
PetDx Funding FAQs
What does PetDx do?
PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.
How much funding has PetDx raised?
PetDx has raised $62.0M across 1 round on record. The most recent is a Series B of $62.0M announced in Dec 2021.
When did PetDx last raise funding?
PetDx's most recent funding round on record is a Series B of $62.0M, announced in Dec 2021.
Who is the CEO of PetDx?
Daniel Grosu is listed as CEO at PetDx.
Where is PetDx headquartered?
PetDx is based in La Jolla, California, United States.
How many employees does PetDx have?
PetDx is in the 51-100 employee band.
How does PetDx's funding compare to other Biotechnology startups?
PetDx's latest round of $62.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's PetDx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PetDx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.